Defining and Targeting BRAF Mutations in Solid Tumors
- 27 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Treatment Options in Oncology
- Vol. 22 (4), 1-15
- https://doi.org/10.1007/s11864-021-00827-2
Abstract
Opinion Statement BRAF mutations are present in up to 8% of human cancers, and comprise a viable therapeutic target in many patients harboring these mutations. Specific BRAF-targeted therapies, such as vemurafenib, dabrafenib, and encorafenib, have transformed treatment of many BRAF-mutated cancers, producing meaningful clinical benefit with more tolerable safety profiles compared to prior standard-of-care treatments. BRAF inhibitors were first approved for use in metastatic melanoma, although resistance almost always limited their long-term effectiveness. Combination therapy with BRAF and MEK inhibitors has proven effective in delaying the onset of resistance, and produces additional clinical benefit across cancers. Although not promising initially in treatment of BRAF-mutated colorectal carcinoma, BRAF inhibitors in colorectal cancer were successfully combined with EGFR inhibitors, resulting in significant treatment response. Refining the use of BRAF and MEK inhibitors in less common tumor types (and for non-V600 mutations) and delaying the development of resistance remain pertinent future considerations in treating BRAF-mutated cancers. In this review, we will discuss the prevalence of BRAF mutations across human cancers and evidence on the efficacy and safety of current management strategies for various BRAF-mutant solid tumors.Keywords
Funding Information
- National Cancer Institute (K23 CA204726)
This publication has 99 references indexed in Scilit:
- Immunological consequences of selective BRAF inhibitors in malignant melanomaOncoImmunology, 2013
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsThe New England Journal of Medicine, 2012
- Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical useJournal of Translational Medicine, 2012
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with VemurafenibCancer Discovery, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon CancersCancer Research, 2005
- Mutations of the BRAF gene in human cancerNature, 2002